Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fevipiprant add-on therapy for uncontrolled asthma
MOH_2018-02-27_000765Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing Fevipiprant 150 mg once daily with Matching placebo once daily (2 arms). Primary endpoint: Efficacy for improvement in lung function. Started Feb 2018; status: completed.
02
Drugs
fevipiprant
03
Conditions
asthma
Beyond the preview
Go deeper on MOH_2018-02-27_000765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-02-27_000765.